Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

hn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. Additional programs include the clinical development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis; and CCX354, a CCR1 antagonist currently in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid a
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... CVS/pharmacy and MinuteClinic health care centers located in ... in 20 states and Washington, D.C. While ... vaccines continue, many states have lifted restrictions, allowing ... shot while supplies last. In addition, seasonal ... at MinuteClinic locations across the country on demand ...
(Date:12/16/2009)... MOUNTAIN VIEW, Calif., Dec. 16 ... Analyst, Zachary Bujnoch, looks forward to speaking ... Health Summit taking place on January 9, ... focuses on the emerging market of consumer-based ... and services. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ...
(Date:12/16/2009)... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Annual J.P. Morgan Healthcare Conference at the Westin ... January 13, 2010. Michael N. Chang, Optimer,s President ... p.m. Pacific Time (5:30 p.m. Eastern Time). ,, ... webcast of this presentation will be accessible on ...
Breaking Medicine Technology:CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 52601 1Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 52601 21 in 7 Low Income Preschoolers Is Obese 52597 11 in 7 Low Income Preschoolers Is Obese 52597 2Registered Dietitian Reveals Chronic Back Pain Relief through Diet in New Book Cookbook and Diet Program 52595 1Registered Dietitian Reveals Chronic Back Pain Relief through Diet in New Book Cookbook and Diet Program 52595 2
(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...
(Date:12/16/2009)... OrthoAccel Technologies, Inc., developers of the ... device to enhance orthodontics, announced Alison Davies as ... Ms. Davies has spent the last fourteen ... industry, most recently for nine years as a ... of Invisalign . ,, (Logo: ...
(Date:12/16/2009)... 16 In a random sampling of ... ME, and Philadelphia, PA, numerous pallets tested positive ... that could potentially create health hazards for consumers. ... previous wood pallet testing conducted in the Washington-Baltimore ... risks to our nation,s food supply from wood ...
(Date:12/16/2009)... in methionine, an amino acid typically found in ... yogurt and seeds, can possibly increase the risk ... by Temple researchers. , The researchers published their ... deposition in a mouse model of Alzheimer,s disease," ... , "When methionine reaches too high a level, ...
(Date:12/16/2009)... program ,, SCHAUMBURG, Ill., Dec. 16 ... deadliest form of skin cancer, almost every hour. ... early. That,s why thousands of dermatologists across the ... communities through the American Academy of Dermatology,s (AAD) ... reached a milestone - two million screenings have ...
Breaking Medicine News(10 mins):Health News:Thriving Bioscience Region Leaves Its Mark 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 2Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 3Health News:Top-performing Sales Manager Joins OrthoAccel Technologies, Inc. in the United Kingdom 4Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4Health News:Diet high in methionine could increase risk of Alzheimer's 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3
... Dr. Philip James, the British chairman of the International ... responsible //for the obesity epidemic in poor countries. ... are those which subsidize and distort the market to ... more expensive," James said at the 10th International Obesity ...
... officials in Northern Ireland are about to launch ... a deadly form of meningitis. //The vaccination against ... childhood immunization programme. ,"Pneumococcal meningitis is ... Research Foundation, said. "Children can effectively die or ...
... researchers have developed a thirst sensor designed to alert the ... avoid dehydration.// ,The device evaluates the relationship between bodily ... body has too little water. ,Four tiny contact ... relaying it to a pocketbook-sized apparatus carried next to the ...
... has reported that its experimental vaccine against a virus ... in the number// of cases and deaths from the ... Cervarix prevents the infection from two strains of the ... percent of cases of cervical cancer. ,At a ...
... tissue suppliers’ scandals, the patients who received tendons, cartilage and ... tests for hepatitis and HIV. This is happening for the ... officials won’t tell the number of people, across the country, ... is difficult to tell about the risk recipients face. ...
... addition to overall research infrastructure upgradation, there are strategies ... for ageing at the Madras Medical College (MMC). ... discussion between an MMC team and Director General N. ... for Medical Research. This was followed by the inauguration ...
Other Medicine News:Health News:Tissue implant scandal heightens FDA’s concer 2Health News:Madras Medical College to have a Centre for preventive cardiology 2